Hematology Analyzers Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Hematology Analyzers Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The hematology analyzers market is projected to register a CAGR of 7.6% during the forecast period (2022-2027).

There was an increasing focus on the hematology parameters for the assessment of COVID-19 around the world. Several studies are carried out in research institutions, and many hospitals started using hematology analyzers to test and monitor COVID-19 patients without spreading the virus. For the practical and efficient screening of large populations for the COVID-19 infection, some research studies from China recommended including white blood cells (WBC) and C-reactive protein (CRP) in laboratory examinations for early monitoring of infection. On March 18, 2020, Sight announced that Israel’s government-run Sheba Tel Hashomer Hospital is using its OLO, the first blood count device for point-of-care to conduct CBC tests to monitor and treat its COVID-19 patients to mitigate the risk of contamination.

Additionally, the review published in Physiological Review-Journal suggests that high levels of an enzyme involved in blood clot prevention may be a common risk factor for developing COVID-19. Furthermore, the correct treatment and management of infection by Coronavirus (COVID-19) in patients affected by hematological disorders may be challenging given the rapid spread of the pandemic and limited literature so far.

Moreover, the major factors for the growth of the hematology analyzers market include the rising burden of blood disorders, increasing technological advancements, and rising adoption rates of automated hematology instruments.

Blood disorders have become a global health issue with different causes and are associated with high mortality. Blood disorders, such as anemia, blood cancers, hemorrhagic conditions, and infections in the blood, affect millions of people each year across all age groups. According to the Australian Government, Department of Health and Aged Care report in 2022, more than 330,000 affected infants are born each year (83% sickle cell disorders and 17% thalassaemias), around 7% of pregnant women are carriers of hemoglobin disorders, and over 1% of couples are at risk at a global level. As per the World Federation of Hemophilia, in 2020, the prevalence of among men hemophilia was found to be around 17 per 100,000 males, globally.

Similarly, according to the World Federation of Hemophilia report updated July 2022, more than 1,125,000 men worldwide have an inherited bleeding disorder, and 418,000 of those have a severe version of the most undiagnosed disease. Early diagnosis and treatment are the best ways to protect the quality of life of a patient with a blood cell disorder. Hence, the increasing burden of blood disorders is likely to drive the market in the future.

However, the high cost of hematology analyzers and time-consuming and stringent regulatory policies associated with the same is restraining the overall market growth.

Key Market Trends3 Part Hematology Analyzer is the Segment by Instruments Expected to Hold Largest Market Share

A 3-part differential cell counter uses Coulter's Principle to find the size and volume of the cell. The sample is lysed and dissolved into an electrolyte solution in a container, which also holds a smaller container. 3-part hematology analyzer systems are ideally suited for physician office laboratories, clinics, and small hospitals that perform moderately complex testing. There is increased interest in 5-part hematology analyzers, however, 3-part hematology analyzers are more cost-effective for routine hematological tests. Furthermore, with advancements in technology and availability of these instruments across the world coupled with affordability the market is projected to have notable growth.

In March 2019, Transasia Bio-Medicals Ltd has launched the 3-Part Differential (3PD) fully automated hematology analyzers, reagents, and controls in India that were manufactured by Erba Lachema a fully owned European subsidiary of Transasia. Later in September 2019, Transasia Bio-Medicals Ltd. announced that it has successfully sold over 1,000 units of its Erba Hematology range of analyzers in India.

In April 2019, Prestige Diagnostics has launched its NEW Hematron 3 PLUS Hematology Analyzer, globally. It is a 3-part differential hematology analyzer capable of performing 18 parameters with 3 histograms.

. Furthermore, convenience and accurate results are the two major reasons driving the growth of the segment over the forecast period.

North America is Expected to Dominate the Studied Market

The market for hematology analyzers in the North American region is growing at a steady pace. This can be attributed to the increasing burden of blood disorders and the growth in the adoption of hematology analyzers by the diagnostic industry. For instance, anemia, which is a common disorder, affects more than three million Americans, particularly women of ‘childbearing age.

According to the Center for Disease Control and Prevention(CDC) report in 2020, Hemophilia A affects 1 in 5000 male births. About 400 babies were born with hemophilia A each year. According to the Leukemia and Lymphoma Society in 2021, every three minutes, a person in the United States is diagnosed with blood cancer. An estimated 186,400 people in the United States were diagnosed with leukemia, lymphoma, or melanoma in 2021.

Many market players are present in the country and are continuously focusing on the development and introduction of novel products. In February 2021 Beckman Coulter launched the DxH 560 AL, a tabletop hematology analyzer designed to reduce time and resource constraints face by small- to mid sized laboratories.

Moreover, in the United States, there are a number of associations helping both clinicians and scientists across the world who are working to conquer such blood diseases. Furthermore, many centers in the state are international leaders in the diagnosis and treatment of blood diseases and collaborate in many research projects to improve diagnosis and treatment options for blood diseases. These factors drive the demand for hematology analyzers in the North American region.

Competitive Landscape

The market studied is a fragmented market owing to the presence of various market players. Some of the market players are Abbott Laboratories, Beckman Coulter Inc. (Danaher Corporation), Bio-Rad Laboratories, Boule Diagnostics AB, F Hoffmann-La Roche Ltd, Hobira Ltd, Nihon Kohden Corporation, Mindray Medical International Limited (Shenzhen Mindray Bio-Medical Electronics Co. Ltd), Siemens Healthineers, and Sysmex Corporation.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.